Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. The company's lead asset includes ficerafusp alfa. Bicara Therapeutics Inc. is based in BOSTON.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-68.00M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.46 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -27.17% |
| Return on Assets (Trailing 12 Months) | -26.05% |
| Current Ratio (Most Recent Fiscal Quarter) | 14.14 |
| Quick Ratio (Most Recent Fiscal Quarter) | 14.14 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $9.04 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.67 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.05 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.24 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 54.78M |
| Free Float | 46.29M |
| Market Capitalization | $994.84M |
| Average Volume (Last 20 Days) | 0.66M |
| Beta (Past 60 Months) | -0.87 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 15.50% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |